Chang Pi-Ling, Cao Minhton, Hicks Patricia
Department of Nutrition Sciences and Comprehensive Cancer Center, 311 Susan Mott Webb Nutrition Sciences Building, 1675 University Boulevard, University of Alabama at Birmingham, Birmingham, AL 35295-3360, USA.
Carcinogenesis. 2003 Nov;24(11):1749-58. doi: 10.1093/carcin/bgg138. Epub 2003 Aug 14.
Osteopontin (OPN) is a secreted, adhesive glycoprotein. Elevated expression of OPN in malignant and benign tumors is postulated to play a role in tumorigenesis. To determine whether OPN induction is required for tumor promotion, we used the in vitro JB6 model known to correlate with tumor promotion in vivo. The skin tumor promoter 12-O-tetradecanoylphorbol-13-acetate (TPA) induces irreversible transformation of JB6 Cl41.5a cells. Concomitantly, TPA markedly stimulates early and persistent OPN expression and secretion for at least 4 days (the time required for these cells to begin to acquire the transformed phenotype) and increases cells' adhesion to OPN. Here, we demonstrated that dexamethasone, a synthetic analog of glucocorticoid, known to inhibit tumor promotion in vivo, not only suppressed TPA-induced OPN mRNA expression and inhibited tumorigenic transformation of JB6 Cl41.5a cells (as previously shown in JB6 Cl22 and Cl41 cells), but also that the addition of OPN partially restored dexamethasone suppression of TPA-induced cell transformation. Therefore, we tested the hypothesis that OPN induction is required for tumor promoter-induced transformation of JB6 cells by examining (i) whether the addition of OPN will induce transformation, (ii) whether antisense OPN expression will inhibit TPA-induced transformation and (iii) if the latter experiment showed inhibition of TPA-induced transformation whether the addition of OPN will rescue this effect. Results indicated that the addition of purified OPN induced a dose-dependent transformation of JB6 cells, as assessed by anchorage- independent growth assay and that this induction was suppressed by antibody to OPN. Furthermore, antisense OPN expressing JB6 clones suppressed TPA-induced OPN synthesis and secretion and inhibited TPA-induced anchorage-independent growth, which was partially rescued by the addition of OPN. In conclusion, OPN induction is required and can be sufficient to induce in vitro cellular transformation of a preneoplastic murine JB6 cell line.
骨桥蛋白(OPN)是一种分泌型黏附糖蛋白。据推测,恶性和良性肿瘤中OPN表达升高在肿瘤发生过程中起作用。为了确定肿瘤促进是否需要诱导OPN,我们使用了已知与体内肿瘤促进相关的体外JB6模型。皮肤肿瘤启动子12 - O - 十四烷酰佛波醇 - 13 - 乙酸酯(TPA)可诱导JB6 Cl41.5a细胞发生不可逆转化。同时,TPA显著刺激OPN的早期和持续表达及分泌至少4天(这些细胞开始获得转化表型所需的时间),并增加细胞对OPN的黏附。在此,我们证明,已知在体内抑制肿瘤促进的糖皮质激素合成类似物地塞米松,不仅抑制TPA诱导的OPN mRNA表达并抑制JB6 Cl41.5a细胞的致瘤转化(如先前在JB6 Cl22和Cl41细胞中所示),而且添加OPN可部分恢复地塞米松对TPA诱导的细胞转化的抑制作用。因此,我们通过检查(i)添加OPN是否会诱导转化,(ii)反义OPN表达是否会抑制TPA诱导的转化,以及(iii)如果后一实验显示抑制TPA诱导的转化,添加OPN是否会挽救这种效应,来检验OPN诱导是肿瘤启动子诱导JB6细胞转化所必需的这一假设。结果表明,通过锚定非依赖性生长测定评估,添加纯化的OPN可诱导JB6细胞发生剂量依赖性转化,并且这种诱导被抗OPN抗体抑制。此外,表达反义OPN的JB6克隆抑制TPA诱导的OPN合成和分泌,并抑制TPA诱导的锚定非依赖性生长,添加OPN可部分挽救这种抑制作用。总之,OPN诱导是必需的,并且足以诱导肿瘤前小鼠JB6细胞系的体外细胞转化。